The origin of many diseases such as Alzheimer's or Parkinson's can be found at the molecular level in our body, in other ...
Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.
What medication is available and what are the side effects? Medication can be helpful in improving the main symptoms of ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Certain cancers and Parkinson's disease are especially difficult to treat, because many of the disease relevant proteins are ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Healthcare Asia on MSN2d
7MM Parkinson’s disease pipeline focuses on disease-modifying agentsThere are a total of 93 products in Phase I-III development for PD treatment. The Parkinson’s disease (PD) therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback